0000000000643923

AUTHOR

Christoph Holtsträter

showing 3 related works from this author

ArtiFuse—computational validation of fusion gene detection tools without relying on simulated reads

2019

Abstract Motivation Gene fusions are an important class of transcriptional variants that can influence cancer development and can be predicted from RNA sequencing (RNA-seq) data by multiple existing tools. However, the real-world performance of these tools is unclear due to the lack of known positive and negative events, especially with regard to fusion genes in individual samples. Often simulated reads are used, but these cannot account for all technical biases in RNA-seq data generated from real samples. Results Here, we present ArtiFuse, a novel approach that simulates fusion genes by sequence modification to the genomic reference, and therefore, can be applied to any RNA-seq dataset wit…

Statistics and ProbabilitySource codeSequence analysisComputer sciencemedia_common.quotation_subjectValue (computer science)Genomicscomputer.software_genreBiochemistryFusion gene03 medical and health sciences0302 clinical medicineSoftwareMolecular BiologyGene030304 developmental biologymedia_common0303 health sciencesSequence Analysis RNAbusiness.industryHigh-Throughput Nucleotide SequencingRNAGenomicsComputer Science ApplicationsComputational MathematicsComputational Theory and Mathematics030220 oncology & carcinogenesisBenchmark (computing)RNAData miningGene FusionbusinesscomputerSoftwareBioinformatics
researchProduct

Bioinformatics for Cancer Immunotherapy

2020

Our immune system plays a key role in health and disease as it is capable of responding to foreign antigens as well as acquired antigens from cancer cells. Latter are caused by somatic mutations, the so-called neoepitopes, and might be recognized by T cells if they are presented by HLA molecules on the surface of cancer cells. Personalized mutanome vaccines are a class of customized immunotherapies, which is dependent on the detection of individual cancer-specific tumor mutations and neoepitope (i.e., prediction, followed by a rational vaccine design, before on-demand production. The development of next generation sequencing (NGS) technologies and bioinformatic tools allows a large-scale an…

0301 basic medicinemedicine.medical_treatmentT cellCancerImmunotherapyBiologymedicine.diseaseBioinformaticsEpitopeBiomarker (cell)03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemmedicine.anatomical_structureCancer immunotherapyAntigenmedicine030215 immunology
researchProduct

Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model

2020

Background: Tumor models are critical for our understanding of cancer and the development of cancer therapeutics. The 4T1 murine mammary cancer cell line is one of the most widely used breast cancer models. Here, we present an integrated map of the genome, transcriptome, and immunome of 4T1. Results: We found Trp53 (Tp53) and Pik3g to be mutated. Other frequently mutated genes in breast cancer, including Brca1 and Brca2, are not mutated. For cancer related genes, Nav3, Cenpf, Muc5Ac, Mpp7, Gas1, MageD2, Dusp1, Ros, Polr2a, Rragd, Ros1, and Hoxa9 are mutated. Markers for cell proliferation like Top2a, Birc5, and Mki67 are highly expressed, so are markers for metastasis like Msln, Ect2, and P…

0301 basic medicineCancer ResearchBiologylcsh:RC254-282computational immunologyMetastasisTranscriptomeFusion gene03 medical and health sciences0302 clinical medicineBreast cancerMammary tumor virusmedicinecancer modelsTriple-negative breast cancerOriginal Research4T1 murine mammary gland tumor cell lineCancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good health030104 developmental biologyOncology030220 oncology & carcinogenesistriple negative breast cancerCancer researchimmunotherapyCD8Frontiers in Oncology
researchProduct